1. 1) De Sousa E Melo F, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity—a multifaceted view. EMBO Rep., 14, 686–695 (2013).
2. 2) Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med., 4, 675–684 (2012).
3. 3) Horiike A, Kudo K, Miyauchi E, Ohyanagi F, Kasahara K, Horai T, Nishio M. Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. Br. J. Cancer, 105, 1131–1136 (2011).
4. 4) Takahashi T, Saikawa Y, Takaishi H, Takeuchi H, Wada N, Oyama T, Fukuda K, Fukada J, Kawaguchi O, Shigematsu N, Kitagawa Y. Phase I study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with resectable advanced gastric cancer (KOGC-01). Anticancer Res., 31, 3079–3083 (2011).
5. 5) Sun TM, Du JZ, Yao YD, Mao CQ, Dou S, Huang SY, Zhang PZ, Leong KW, Song EW, Wang J. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano, 5, 1483–1494 (2011).